Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan

被引：0
|
作者：
C. Arrichiello
L. Aloj
M. Mormile
L. D’Ambrosio
F. Frigeri
C. Caracò
M. Arcamone
F. De Martinis
A. Pinto
S. Lastoria
机构：
[1] Istituto Nazionale per lo Studio e la Cura dei Tumori,Nuclear Medicine Department
[2] Fondazione “G. Pascale”,Hematology
[3] Istituto Nazionale per lo Studio e la Cura dei Tumori,Oncology and Stem Cells Transplantation Unit, Department of Hematology
[4] Fondazione “G. Pascale”,IRCCS
[5] Istituto Nazionale per lo Studio e la Cura dei Tumori,undefined
[6] Fondazione “G. Pascale”,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2012年 / 39卷
关键词：
Radioimmunotherapy; Ibritumomab tiuxetan; Non-Hodgkin’s lymphoma; Dosimetry; Bremsstrahlung imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：956 / 966
页数：10
相关论文
共 50 条
  • [41] MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
    Fisher, Darrell R.
    Shen, Sui
    Meredith, Ruby F.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (04) : 644 - 652
  • [42] Radiation dose measurements for personnel performing 90Y-ibritumomab tiuxetan administration: a comparison between two injection methods for dose reduction
    Law, M.
    Liu, R.
    Ng, S.
    Luk, M. Y.
    Leung, T. W.
    Au, G. K. H.
    BRITISH JOURNAL OF RADIOLOGY, 2009, 82 (978): : 491 - 496
  • [43] RIT WITH 90Y-IBRITUMOMAB TIUXETAN IMPROVES THE RESPONSE IN AGGRESSIVE NON-HODGKIN LYMPHOMA
    Montes Limon, A.
    Andrade Campos, M.
    Murillo Flores, I.
    Grasa Ulrich, J. M.
    Lievano, P.
    Baringo, T.
    Giraldo Castellanos, P.
    HAEMATOLOGICA, 2012, 97 : 667 - 668
  • [44] Bremsstrahlung Imaging: A Valid Alternative For Dose Estimation In Patients Undergoing 90Y Zevalin Treatment
    Arrichiello, C.
    Mormile, M.
    D'Ambrosio, L.
    De Martinis, F.
    Squame, E.
    Frigeri, F.
    Arcamone, M.
    Aurilio, M.
    Aloj, L.
    Lastoria, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S262 - S262
  • [45] A dosimetry tool for three-dimensional tumor dose assessment in radioimmunotherapy with 90Y-ibritumomab-tiuxetan
    D'Arienzo, M.
    Cicone, F.
    Bagni, O.
    Brainovich, V.
    Chiacchiararelli, L.
    Scopinaro, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S238 - S239
  • [46] Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma
    Lossos, Izidore S.
    Reis, Isildinha M.
    Rosenblatt, Joseph D.
    Alderuccio, Juan Pablo
    LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3234 - 3238
  • [47] Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab
    Rossignol, J.
    Terriou, L.
    Robu, D.
    Willekens, C.
    Hivert, B.
    Pascal, L.
    Guieze, R.
    Trappe, R.
    Baillet, C.
    Huglo, D.
    Morschhauser, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (07) : 1976 - 1981
  • [48] Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)
    Papi, Stefano
    Martano, Luigi
    Garaboldi, Lucia
    Rossi, Annalisa
    Cremonesi, Marta
    Grana, Chiara Maria
    Paolucci, Daniele
    Sansovini, Maddalena
    Paganelli, Giovanni
    Chinol, Marco
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (01) : 85 - 93
  • [49] Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin®) treatment in follicular non-Hodgkin's lymphoma
    Otte, Andreas
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2008, 11 (01): : 12 - 15
  • [50] Cost-effectiveness of 90Y-ibritumomab tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma.
    Thompson, S
    van Agthoven, M
    BLOOD, 2005, 106 (11) : 685A - 685A
12345